MBC News from 2021 AACR Meeting
Click here for MBC-related research and reports from AACR 2021.
Learn about the current research on HR-positive, HER2-Positive, Triple-Negative MBC, and other MBC subtypes from the 2021 St. Gallen International Breast Cancer Conference.
Learn about research on HR+ MBC treatment, including AKT inhibitors, oral SERDs, CDK 4/6 inhibitors, and more.
Next-generation sequencing (NGS) is when all of the genes in a tumor are tested for genomic mutations. Read the discussions about whether NGS improves survival and quality of life, and the ESMO recommendations regarding NSG for patients with metastatic cancers (including breast).
Which therapy to use for the first, second or third line of treatment for metastatic breast cancer is now under rigorous research as more new therapies are available for treating MBC.
Did you know that some breast cancers can be defined as estrogen receptor low (ER-low) breast cancer?
When you’re first diagnosed, a pathologist runs a series of lab tests on the cancer cells to see what drives the breast cancer to grow. Estrogen receptor positive (ER positive) breast cancer cells have proteins that respond to signals from estrogen, telling the cells to grow. Your pathology report will tell you whether the cancer is ER positive, and how many cells in the tumor sample had estrogen receptors.
Right now, any breast cancer with at least 1% of tested cells showing estrogen receptors is considered ER positive. But researchers have found that ER positive cancers that have a low number of cells with estrogen receptors may respond differently to treatment. These breast cancers are called ER-low.
To learn more about reading your test results, understanding ER-low, and what current guidelines are for treating estrogen receptor low breast cancer, see below.
The U.S. Food and Drug Administration (FDA) approved Piqray® for treating advanced breast cancer. Use the links below to learn more about the FDA approval and how PI3K inhibitors work and to find clinical trials on Metastatic Trial Search for Piqray and other therapies being tested in patients whose tumors have a PIK3CA mutation.